Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Development of new generation influenza vaccines: recipes for success?

Pronker ES, Claassen E, Osterhaus AD.

Vaccine. 2012 Dec 7;30(51):7344-7. doi: 10.1016/j.vaccine.2012.09.071. Epub 2012 Oct 5. Review.

PMID:
23044407
2.

Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline.

Davis MM, Butchart AT, Wheeler JR, Coleman MS, Singer DC, Freed GL.

Vaccine. 2011 Nov 28;29(51):9414-6. doi: 10.1016/j.vaccine.2011.09.128. Epub 2011 Oct 12.

PMID:
22001883
3.

The gold industry standard for risk and cost of drug and vaccine development revisited.

Pronker ES, Weenen TC, Commandeur HR, Osterhaus AD, Claassen HJ.

Vaccine. 2011 Aug 11;29(35):5846-9. doi: 10.1016/j.vaccine.2011.06.051. Epub 2011 Jun 29. Review.

PMID:
21722688
4.

Getting pharmaceutical R&D back on target.

Bunnage ME.

Nat Chem Biol. 2011 Jun;7(6):335-9. doi: 10.1038/nchembio.581. No abstract available.

PMID:
21587251
5.

Trial watch: Phase II failures: 2008-2010.

Arrowsmith J.

Nat Rev Drug Discov. 2011 May;10(5):328-9. doi: 10.1038/nrd3439. No abstract available.

PMID:
21532551
6.

Trial watch: phase III and submission failures: 2007-2010.

Arrowsmith J.

Nat Rev Drug Discov. 2011 Feb;10(2):87. doi: 10.1038/nrd3375. No abstract available.

PMID:
21283095
7.

A comparison of the use of economics in vaccine expert reviews.

Jacobs P, Ohinmaa A.

Vaccine. 2010 Apr 1;28(16):2841-5. doi: 10.1016/j.vaccine.2010.01.056. Epub 2010 Feb 12.

PMID:
20153796
8.

Trends in risks associated with new drug development: success rates for investigational drugs.

DiMasi JA, Feldman L, Seckler A, Wilson A.

Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Review.

PMID:
20130567
9.

The expanding vaccine development pipeline, 1995-2008.

Davis MM, Butchart AT, Coleman MS, Singer DC, Wheeler JR, Pok A, Freed GL.

Vaccine. 2010 Feb 3;28(5):1353-6. doi: 10.1016/j.vaccine.2009.11.007. Epub 2009 Nov 21. Review.

PMID:
19932670
10.

Estimated research and development costs of rotavirus vaccines.

Light DW, Andrus JK, Warburton RN.

Vaccine. 2009 Nov 5;27(47):6627-33. doi: 10.1016/j.vaccine.2009.07.077. Epub 2009 Aug 7.

PMID:
19665605
11.

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.

Collin N, de Radigu├Ęs X; World Health Organization H1N1 Vaccine Task Force.

Vaccine. 2009 Aug 20;27(38):5184-6. doi: 10.1016/j.vaccine.2009.06.034. Epub 2009 Jun 27.

PMID:
19563891
12.

The transition from phase II to phase III studies.

Berthold DR, Gulamhusein A, Jackson JI, Tannock IF.

J Clin Oncol. 2009 Mar 1;27(7):1150-1. doi: 10.1200/JCO.2008.21.1938. Epub 2009 Jan 26. No abstract available.

PMID:
19171698
13.

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans.

Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG.

Lancet Infect Dis. 2008 Oct;8(10):650-8. doi: 10.1016/S1473-3099(08)70232-9.

PMID:
18922487
14.

Vaccine manufacturing: challenges and solutions.

Ulmer JB, Valley U, Rappuoli R.

Nat Biotechnol. 2006 Nov;24(11):1377-83.

PMID:
17093488
15.

The 'not invented here' myth.

Lou K, de Rond M.

Nat Rev Drug Discov. 2006 Jun;5(6):451-2. No abstract available.

PMID:
16821286
16.

Human vaccine research and development: an overview.

Kieny MP, Girard MP.

Vaccine. 2005 Dec 30;23(50):5705-7. Epub 2005 Aug 10. Review.

PMID:
16182415
17.

How can we avoid the productivity gap?

Carney S.

Drug Discov Today. 2005 Aug 1;10(15):1011-3. No abstract available.

PMID:
16055012
18.

Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.

Danzon PM, Nicholson S, Pereira NS.

J Health Econ. 2005 Mar;24(2):317-39. Epub 2005 Jan 25.

PMID:
15721048
19.

Can the pharmaceutical industry reduce attrition rates?

Kola I, Landis J.

Nat Rev Drug Discov. 2004 Aug;3(8):711-5. doi: 10.1038/nrd1470. Review. No abstract available.

PMID:
15286737
20.

The price of innovation: new estimates of drug development costs.

DiMasi JA, Hansen RW, Grabowski HG.

J Health Econ. 2003 Mar;22(2):151-85.

PMID:
12606142

Supplemental Content

Support Center